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Abstract
Using English Wikipedia network of more than 5 million articles we analyze interactions
and interlinks between 34 largest pharmaceutical companies, 195 world countries, 47
rare renal diseases and 37 types of cancer. The recently developed algorithm of reduced
Google matrix (REGOMAX) allows to take into account direct Markov transitions
between these articles but also all indirect ones generated by the pathways between
these articles via the global Wikipedia network. Thus this approach provides a compact
description of interactions between these articles that allows to determine the friendship
networks between articles, the PageRank sensitivity of countries to pharmaceutical
companies and rare renal diseases. We also show that the top pharmaceutical
companies of Wikipedia PageRank are not those of the top list of market capitalization.
Introduction 1
The improvement of human health and its treatment from various diseases is the vital 2
task of human society [1]. The creation of efficient medicaments and drugs is now 3
mainly controlled by large biotechnology and pharmaceutical companies. The 34 world 4
largest companies are listed in Wikipedia [2]. The analysis of interactions between these 5
companies and their influence to various diseases is an important but not easy task. 6
Here we develop the data mining approach to this task using the directed network of 7
articles of English Wikipedia, dated by May 2017, generated by citation links between 8
articles. At present Wikipedia accumulates a huge amount of human knowledge 9
exceeding the one of Encyclopedia Britanica in volume and accuracy of articles devoted 10
to scientific topics [3]. Scientific articles are actively maintained as it is shown by the 11
example of articles on biomolecules [4]. The academic research and analysis of 12
Wikipedia information is growing with the development of new tools and methods as 13
reviewed in [5]. The quality of Wikipedia articles is improving with time as it is shown 14
by the analysis reported in [6]. 15
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At present there is a variety of methods for the analysis and the characterization of 16
complex networks (see e.g. [7]). The most used of them is the PageRank algorithm 17
invented by Brin and Page in 1998 for ranking the World Wide Web (WWW) sites [8]. 18
The detailed descriptions of the algorithm and the mathematical properties of the 19
related Google matrix are given in [9] while a variety of applications of the Google 20
matrix to real directed networks are described in [10]. The applications of Google 21
matrix methods to Wikipedia networks of 24 language editions allowed to obtain a 22
reliable ranking of historical figures over 15 centuries of human history [11] and of world 23
universities [12]. 24
Recently the reduced Google matrix (REGOMAX) algorithm has been proposed for 25
the analysis of the effective interactions and links between a selected subset of nodes of 26
interest embedded in a much larger global network [13]. The REGOMAX algorithm 27
originates from the scattering theory of nuclear and mesoscopic physics and field of 28
quantum chaos. Its efficiency has been demonstrated for Wikipedia networks recovering 29
effective interactions between politicians [14], geopolitical relations and links between 30
world countries [15], universities [16] and banks [17]. 31
The applications of REGOMAX approach were also performed for networks of 32
protein-protein interactions [18], and for Wikipedia networks to determine influence of 33
infectious diseases [19], drugs and cancers [20]. Here we extend this approach to analyze 34
the global influence and their mutual interactions of the 34 world largest biotechnology 35
and pharmaceutical companies [2]. We use the Wikipedia network with 5 416 537 36
articles and establish sensitivities of 195 countries to these companies. We also 37
construct the interaction networks between these companies and 47 rare renal diseases 38
and 37 types of cancer. The number of people suffered from cancer was about 32.6 39
million worldwide in 2012 with annual increase 6-9 million people [21]. The number of 40
people suffered from rare diseases reaches 350 million globally [22]. Despite cancer and 41
80% of rare diseases are genetic diseases, development of drugs for these two groups of 42
disease meets some different challenges. One of fundamental challenge of drug 43
development for rare diseases is their huge number and diversity. It’s known more than 44
7 000 rare diseases [22] whereas number of known cancer types is quite limited. Big 45
number and diversity rare diseases leads to the problems of drug development because 46
small number of patients for individual disease, the logistics involved in reaching widely 47
dispersed patients, the lack of validated biomarkers and surrogate end-points, and 48
limited clinical expertise and expert centers [23]. Representation of information about 49
cancer and rare diseases in Wikipedia clearly illustrates difference between cancers and 50
rare diseases. Most of cancer types listed on site of National Cancer Institute [24] are 51
represented in Wikipedia. In the same time only 8.5% and 15% of phenotype described 52
in Orphanet and OMIM correspondingly have topics in Wikipedia. For our calculation 53
we use only 47 rare renal diseases listed in [25] and represented on Wikipedia. 54
We hope that our results will allow to obtain a better understanding of the 55
pharmaceutical companies influence on these diseases and to obtain a specialization 56
profiles of pharmaceutical companies. 57
The paper is constructed as follows: the mathematical methods are described in 58
Section Methods and data are overviewed in Section Datasets. The two following 59
Sections are devoted to the presentation of Results and of the Discussion. 60
Methods 61
Google matrix construction 62
The detailed description of Google matrix construction and its properties are given 63
in [9, 10] so that here we provide only a brief description for reader convenience. 64
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The Google matrix G is built from the adjacency matrix Aij with elements being 1 if 65
article (node) j points to article (node) i and zero otherwise. The matrix elements have 66
the standard form Gij = αSij + (1− α)/N [8–10], where S is the matrix describing 67
Markov transitions with elements Sij = Aij/kout(j) if the out-degree of node j is 68
kout(j) =
∑N
i=1Aij 6= 0, or Sij = 1/N if j has no outgoing links (dangling node), i.e., 69
kout(j) = 0. Here 0 < α < 1 is the damping factor and below we use its standard value 70
α = 0.85 [9]. We note that for the range 0.5 ≤ α ≤ 0.95 the results are not sensitive to 71
α [9, 10]. Thus, for a random surfer, jumping from one node to another, the probability 72
to jump to any node is (1− α). 73
The leading right eigenvector P of G, called the PageRank vector, is the solution of 74
the equation GP = λP for the unit eigenvalue λ = 1. According to the 75
Perron-Frobenius theorem the PageRank vector components Pj give probabilities to find 76
a random surfer on a node j, therefore
∑
j Pj = 1 [9]. We order all nodes by decreasing 77
probability Pj numbered by PageRank index K = 1, 2, ...N with a maximal probability 78
at K = 1 and minimal at K = N . The numerical computation of Pj probabilities is 79
done efficiently with the PageRank iteration algorithm described in [8, 9]. 80
It is also useful to consider the original network with inverted direction of links. 81
After inversion the Google matrix G∗ is constructed via the same procedure with 82
G∗P ∗ = P ∗. The matrix G∗ has its own PageRank vector P ∗ called CheiRank [26,27] 83
(see also [10]). Its components are also probabilities that can be again ordered in a 84
decreasing order with CheiRank index K∗ with highest component of P ∗ at K∗ = 1 and 85
smallest at K∗ = N . On average, the high values of P (P ∗) correspond to nodes with 86
many ingoing (outgoing) links [9, 10]. Thus PageRank stress the article importance on 87
the network while CheiRank highlights the communicative properties of articles. 88
Reduced Google matrix 89
The REGOMAX algorithm was proposed in [13] and it is described in detail 90
in [14–16,18]. Here we give the main elements of this method using the notations of [14]. 91
This algorithm computes efficiently a reduced Google matrix of size Nr ×Nr that 92
captures the full contributions of direct and indirect pathways happening in the full 93
Google matrix between Nr nodes of interest. For the selected Nr nodes their PageRank 94
probabilities are the same as for the global network with N nodes, up to a constant 95
multiplicative factor taking into account that the sum of PageRank probabilities over 96
the Nr nodes is unity. The computation of GR determines also a decomposition of GR 97
into matrix components that clearly distinguish direct from indirect interactions, 98
GR = Grr +Gpr +Gqr [14]. Here Grr is given by the direct links between selected Nr 99
nodes in the global matrix G with N nodes. In fact, Gpr is rather close to the matrix in 100
which each column is equal to the PageRank vector Pr. This ensures that PageRank 101
probabilities of GR are the same as for G (up to a constant multiplier). Due to that Gpr 102
doesn’t provide much information about direct and indirect links between selected 103
nodes. 104
Thus the most interesting and nontrivial role is played by Gqr. It takes into account 105
all indirect links between selected nodes emerging due to multiple pathways via the 106
global network nodes N (see [13,14]). The matrix Gqr = Gqrd +Gqrnd has diagonal 107
(Gqrd) and non-diagonal (Gqrnd) parts with Gqrnd including indirect interactions 108
between nodes. The exact formulas for the three components of GR are given in [13, 14]. 109
A useful additional characteristic provided by GR matrix is the sensitivity of the 110
PageRank probability to the variation of a specific link between a pair of nodes chosen 111
among the Nr nodes of interest. The useful results obtained with this method have 112
been demonstrated in [15–17,19,20]. Thus, in our case, the sensitivity of a country c to 113
a specific pharmaceutical company ph is determined by a change of matrix element 114
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GR c,ph by a factor (1 + δ) with δ  1 and renormalization to unity of the sum of the 115
column matrix elements associated with pharmaceutical company ph. Then the 116
sensitivity is defined by the logarithmic derivative of PageRank probability P (c) 117
associated to country c, D(ph→ c, c) = d lnP (c)/dδ (diagonal sensitivity). In a similar 118
way we determine the sensitivity of countries to a rare renal disease rd: 119
D(rd→ c, c) = d lnP (c)/dδ. 120
Table 1. List of the 34 largest pharmaceutical companies ranked by the
relative PageRank index Kr of their corresponding articles in Wikipedia.
The KLMC index gives the ranking by the largest market capitalization since 2000 [2]
and the KMC index gives the ranking by market capitalization in 2017 [2].
Kr KLMC KMC Company K KLMC KMC Company
1 2 3 Pfizer 18 18 18 Biogen
2 8 15 GSKa 19 28 28 Mylan
3 14 10 Bayer 20 7 13 Gilead
4 1 1 J&Jb 21 21 21 Shire
5 3 4 Novartis 22 23 23 Takeda
6 6 6 Merck 23 29 27 Astellas
7 16 14 Lilly 24 32 29 Daiichi Sankyo
8 4 2 Roche 25 5 5 AbbVie
9 19 16 AstraZeneca 26 22 22 Regeneron
10 10 9 Sanofi 27 33 31 Eisai
11 15 11 BMSc 28 20 19 Stryker
12 13 12 Abbott 29 34 33 BioMarin
13 24 24 Illumina 30 27 26 Zoetis
14 11 8 Amgen 31 25 25 Vertex
15 9 7 Novo Nordisk 32 26 30 Alexion
16 12 20 Allergan 33 31 34 Perrigo
17 17 17 Celgene 34 30 32 Incyte
aGSK: GlaxoSmithKline, bJ&J: Johnson & Johnson, cBMS: Bristol-Myers Squibb.
Datasets 121
We consider the English Wikipedia edition collected in May 2017 with N = 5416537 122
articles (nodes) and Nl = 122232932 hyperlinks between articles. This network has been 123
considered also in [16, 17, 19, 20]. For the REGOMAX analysis we select Nc = 195 world 124
countries (see the list and PageRank order in [19,20]), Nph = 34 of the largest 125
pharmaceutical companies (see Table 1), Nrd = 47 rare renal diseases (see Table 2), and 126
Ncr = 37 types of cancer listed in [20]. Thus in total we consider 127
Nr = Nc +Nph +Nrd +Ncr = 313 Wikipedia articles as nodes of interest. Compared to 128
the studies reported in [20] the new nodes correspond to Nph = 34 pharmaceutical 129
companies and Nrd = 47 rare renal diseases. The relative PageRank order of the 130
Nph = 34 companies is given in Table 1, and of the Nrd = 47 rare renal diseases in 131
Table 2. 132
In Table 2, the 47 renal rare diseases can be grouped in five categories to which we 133
have for convenience associated a color: congenital abnormalities of the kidney and 134
urinary tract (red), glomerular diseases (blue), renal tubular diseases and metabolic 135
diseases (gold), nephrolithiasis (cyan), and ciliopathies and nephronophthisis (green) in 136
manner they were classified in [25]. From 166 genetic disorders of renal growth, 137
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Table 2. List of 47 rare renal diseases ranked by the relative PageRank index Kr of their corresponding
articles in Wikipedia. The relative CheiRank index, K∗r , is also given. The list of rare renal diseases is
splitted in 5 categories with the following color code:  Congenital abnormalities of the kidney and urinary
tract,  Glomerular diseases,  Renal tubular diseases and metabolic diseases,  Nephrolithiasis and 
Ciliopathies and Nephronophthisis.
Kr K
∗
r Rare renal disease Short name
1 6 Alport syndrome Alport
2 1 Bardet–Biedl syndrome Bardet–Biedl
3 7 Fabry disease Fabry
4 2 Kallmann syndrome KS
5 4 Renal tubular acidosis RTA
6 5 Cystinuria Cystinuria
7 14 Renal agenesis Renal agenesis
8 16 Nephronophthisis Nephronophthisis
9 33 X-linked hypophosphatemia XLH
10 8 Bartter syndrome Bartter
11 41 Xanthinuria Xanthinuria
12 3 Oculocerebrorenal syndrome Oculocerebrorenal
13 17 Nail–patella syndrome Nail-patella
14 45 Familial renal amyloidosis Amyloidosis
15 9 Episodic ataxia EA
16 24 Gitelman syndrome Gitelman
17 21 Medullary cystic kidney disease MCKD
18 32 Familial hypocalciuric hypercalcemia FHH
19 42 Renal glycosuria Glycosuria
20 40 Fanconi-Bickel syndrome Fanconi-Bickel
21 23 Liddle’s syndrome Liddle
22 31 Hypomagnesemia with secondary hypocalcemia HSH
23 13 Fraser syndrome Fraser
24 36 WAGR syndrome WAGR
25 19 Branchio-oto-renal syndrome BOR
26 26 Townes–Brocks syndrome Townes–Brocks
27 44 Autosomal dominant hypophosphatemic rickets ADHR
28 18 Orofaciodigital syndrome 1 Orofaciodigital
29 28 Denys–Drash syndrome DDS
30 10 Perlman syndrome Perlman
31 11 Simpson–Golabi–Behmel syndrome SGBS
32 12 Caroli disease Caroli
33 25 Congenital nephrotic syndrome GNS
34 39 Fechtner syndrome Fechtner
35 27 Abderhalden–Kaufmann–Lignac syndrome AKL
36 22 Lysinuric protein intolerance LPI
37 47 Majewski’s polydactyly syndrome Majewski
38 20 Urofacial syndrome Urofacial
39 15 Barakat syndrome Barakat
40 35 Dicarboxylic aminoaciduria DCBXA
41 38 MODY 5 MODY 5
42 30 Papillorenal syndrome Papillorenal
43 43 OCRL OCRL
44 37 COQ9 COQ9
45 29 Juvenile nephronophthisis J. nephronophthisis
46 46 Renal-hepatic-pancreatic dysplasia RHPD
47 34 Conorenal syndrome Conorenal
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structure renal function listed in article for 47 phenotypes (28%) only corresponding 138
articles were found on Wikipedia. 139
Results 140
1
10
102
103
104
105
106
1 10 102 103 104 105 106
K
*
K
Fig 1. Density of Wikipedia articles in the PageRank-CheiRank plane
(K,K∗). Data are averaged over a 100× 100 grid for (log10K, log10K∗) spanning the
domain [0, log10N ]× [0, log10N ]. Density of articles ranges from very low density
(purple tiles) to very high density (bright yellow tiles). The absence of article is
represented by black tiles. The superimposed white circles give the positions of articles
devoted to 195 countries, the red circles are the positions of articles devoted to 230 kind
of infectious diseases studied in [19], the green circles are the positions of 37 articles of
cancers studied in [20], the gold circles mark the positions of 47 articles of rare renal
diseases and the purple circles give the positions of 34 articles of pharmaceutical
companies.
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PageRank vs CheiRank distributions 141
In Fig. 1 we show the coarse-grained distribution of all N Wikipedia articles on 142
PageRank-CheiRank plane (K,K∗) in logarithmic scale. On this plane we plot positions 143
of 195 countries (white circles), 37 cancer types (green circles), 47 rare renal diseases 144
(gold circles), 34 pharmaceutical companies (purple circles) and we also add the 230 145
infectious diseases (red circles) studied in [19]. As usual countries take the top 146
PageRank positions (see also [10]), then we have the groups of infectious diseases and 147
cancers. The group of rare diseases starts approximately at the middle of the group of 148
cancers that corresponds to the fact that these 47 diseases are rare. The head of 149
parmaceutical companies group is a bit behind the head of the group of cancers. In the 150
global PageRank list the top 3 of each group are K = 1 US, K = 2 France, K = 3 151
Germany for countries, K = 639 tuberculosis, K = 810 HIV/AIDS, K = 1116 malaria 152
for infectious diseases [19], K = 3478 lung cancer, K = 3788 breast cancer, K = 3871 153
leukemia for cancers [20], K = 9345 Pfizer, K = 11290 GlaxoSmithKline, K = 13737 154
Bayer for pharmaceutical companies, K = 156963 Alport syndrome, K = 161731 155
Bardet–Biedl syndrome, K = 174780 Fabry disease for rare renal diseases. 156
In Table 1 we give the PageRank relative rank Kr list of 34 pharmaceutical 157
companies. We also give in this table the rank KLMC of these companies from the 158
largest market capitalization ranking [2] and the rank KMC from the market 159
capitalization ranking in 2017 [2]. 160
The distribution of companies on the rank plane (Kr,KLMC) is shown in Fig. 2. 161
The richest company Johnson & Johnson (J&J) is only at the 4th position in PageRank 162
(Kr = 4). This shows that its public influence in Wikipedia is well behind its first 163
position in market capitalization. We can also note that AbbVie, spin-off of Abbott 164
laboratories, which performed the 5th most important market capitalization since 2000 165
is with Kr = 25 among the less influential of the considered pharmaceutical companies. 166
In contrast Pfizer is the most influential company on Wikipedia with Kr = 1 and 167
KLMC = 2. A significant influence in Wikipedia is found for pharmaceutical companies 168
with a top Kr position and a somewhat worse KLMC , such companies are 169
GlaxoSmithKline (GSK) with Kr = 2 and KLMC = 8 and Bayer with Kr = 3 and 170
KLMC = 14. As a summary, if the influence of the pharmaceutical companies were 171
strictly proportional to their richness, the companies would lie on the diagonal 172
(Kr = KLMC), thus here companies above (below) the diagonal have an excess (lack) of 173
influence in Wikipedia in comparison with their market capitalization. 174
The overlap η(j) between the two ranking lists Kr and KLMC (see Table 1) and also 175
between the two ranking lists Kr and KMC (see Table 1) are shown in Fig. 3. We see 176
that for the first three positions the overlap is only η = 1/3. This shows that the most 177
rich pharmaceutical companies still can improve significantly their public visibility at 178
Wikipedia. At present Wikipedia web site is at the 5th position among the most visited 179
web sites of the world [28] and the improvement of Wikipedia article content can bring 180
significantly better world visibility of a company, being free of charge. Nevertheless 7 of 181
the top 10 most influential pharmaceutical companies in Wikipedia are also among the 182
top 10 largest market capitalization since 2000 and among the top 10 market 183
capitalization in 2017. 184
The distribution of 47 articles of rare renal diseases on the PageRank-CheiRank 185
plane if shown in Fig. 4. The top three PageRank positions are taken by Alport 186
syndrome, Bardet-Biedl syndrome, Fabry disease (Kr = 1, 2, 3) so that these are most 187
influential rare renal diseases. The top three CheiRank positions are Bardet-Biedl 188
syndrome, Kallmann syndrome, Oculocerebrorenal syndrome (K∗r = 1, 2, 3) thus being 189
the most communicative articles of among the 47 articles devoted to rare renal diseases. 190
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Fig 2. Distribution of pharmaceutical companies ranked by the largest
market capitalization index, KLMC , and by the relative PageRank index,
Kr, of their article in Wikipedia. See rankings in Table 1.
Example of reduced Google matrix GR 191
We will consider Wikipedia articles (nodes of interest) among the 313 selected articles 192
(nodes) including countries (Nc = 195), pharmaceutical companies (Nph = 34), cancers 193
(Ncr = 37) and rare renal diseases (Nrd = 47). Since the interactions between countries 194
and cancers have been analyzed in [20], we show below other interactions such as 195
between pharmaceutical companies and countries, cancers, rare renal diseases, and 196
between rare renal diseases and countries. In Fig. 5 we show the 81× 81 reduced Google 197
matrix GR (top left panel) and its Grr (top right panel), Gpr (bottom left panel), Gqr 198
(bottom right panel) components associated to pharmaceutical companies and rare renal 199
diseases. Focusing on GR (Fig. 5 top left panel), the first 34× 34 block diagonal 200
sub-matrix (delimited by the purple square) gives the effective directed links between 201
pharmaceutical companies. The remaining 47× 47 block diagonal sub-matrix 202
(sub-divided in five block diagonal sub-matrices delimited by colored square; the rare 203
renal diseases color code is given in Table 2) gives the effective directed links between 204
rare renal diseases. The 47× 34 (34× 47) rectangular sub-matrix gives the effective 205
April 20, 2019 8/26
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/614016doi: bioRxiv preprint first posted online Apr. 29, 2019; 
0
0.2
0.4
0.6
0.8
1
1 345 10 15 20 25 30
η(
j)
j
LMC (2000-2018)
MC (2017)
Fig 3. Overlap between the PageRanking of pharmaceutical companies
articles in Wikipedia and the ranking of pharmaceutical companies by
market capitalizations. The overlap function is η(j) = jph/j where jph is the
number of common pharmaceutical companies in the top j of two lists: the
PageRanking of pharmaceutical companies articles in Wikipedia (see first column of
Tab. 1) and the list of pharmaceutical companies ranked by market capitalization in
2017 (red curve, see third column in Tab. 1) and by the largest market capitalization
since 2000 (black curve, see second column Tab. 1).
directed links from (pointing to) pharmaceutical companies to (from) rare renal diseases. 206
We clearly see that the Gpr components gives us back information about the global 207
PageRank, indeed each column are similar. We retrieve the fact that Wikipedia articles 208
about top pharmaceutical companies are better PageRanked that those concerning rare 209
renal diseases. The 22 most influential companies have a global PageRank index from 210
K ∼ 104 to K ∼ 105 (see Fig. 1), whereas the most influential rare renal disease have a 211
PageRank index above K ∼ 105. This is also clearly seen in the Gpr matrix picture 212
(Fig. 5, bottom left panel). The direct links are visible on the Grr matrix (Fig. 5 top 213
right panel) which gives a picture of the adjacency matrix A. We observe that direct 214
links are denser in the block diagonal of pharmaceutical companies than in the rare 215
renal diseases one. In the pharmaceutical companies sector we have many direct links 216
with almost every Wikipedia articles devoted to a pharmaceutical company pointing 217
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Fig 4. Distribution of Nrd = 47 articles of rare renal diseases on the plane of
relative PageRank-CheiRank indexes (Kr,K
∗
r ); positions in the plane are given
by golden circles with short disease names.
toward at least another one (with exceptions of Alexion, BioMarin, Novo Nordisk). This 218
is due to the very competitive economical industry where drug department acquisitions 219
from a company to another is routine. Still from Fig. 5 top right panel, from the rare 220
renal diseases sector we observe that the few direct links concern rare renal diseases 221
belonging to the same category (pixels enclosed in the red, blue, gold cyan and green 222
squares). The exceptions are nephronophthisis, which belongs to the ciliopathies 223
category, and medullary cystic kidney disease, which belongs to the renal tubular 224
diseases and metabolic diseases category; each one these diseases directly point to the 225
other. In fact these two diseases share similar morphological and clinical features (see, 226
e.g., [29]) which explains reciprocal direct links between these diseases. We also observe 227
that none of the Wikipedia articles devoted to the largest market capitalization 228
pharmaceutical companies directly cites one of the rare renal diseases. This observation 229
highlights the orphan status of these diseases. The only direct link existing between 230
pharmaceutical companies and rare renal diseases is Fabry disease pointing toward Shire 231
which manufactures Replagal, a dedicated drug for Fabry disease [30]. Finally, the Gqr 232
matrix component (Fig. 5 bottom right panel) gives indirect links, some of them being 233
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Fig 5. Reduced Google matrix GR of pharmaceutical companies and rare renal diseases. We show the reduced
Google matrix GR (top left panel) and its three components Grr (top right panel), Gpr (bottom left panel), and Gqrnd
(bottom right panel). Each “pixel” represents a matrix entry which the amplitude is given by a color. Color bars gives the
corresponds between matrix entry amplitudes and colors. For each 81× 81 matrix the first 34 entries correspond to
pharmaceutical companies (ordered as in Table 1) and the other 47 entries correspond to rare renal diseases (ordered by
categories then by PageRank order inside each category, see Table 2). The first 34× 34 block diagonal sub-matrix (purple
square) corresponds to directed interactions between pharmaceutical companies. The other five smallest block diagonal
sub-matrices correspond to directed interactions between rare renal diseases belonging to one of the five categories defined in
Table 2. The colors of the squares correspond to color categories given in Table 2. For the sake of visibility horizontal and
vertical white dashed lines are drawn after every 20 entries.
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purely hidden links since they do not appear in the Grr matrix component (Fig. 5 top 234
right panel). The Gqr matrix component reveals many hidden links between 235
pharmaceutical companies which are certainly due to the complex economic 236
entanglements of these companies. The two most intense hidden links appear from 237
Alexion to Shire and from Abbott to Johnson & Johnson. Many indirect pathways 238
through the entire Wikipedia network contribute to these hidden links. E.g., one of the 239
shortest path going from Alexion to Shire is the Alexion → Ludwig N. Hantson → Shire 240
link [31]. Indeed, Ludwig N. Hantson has been named Alexion Pharmaceuticals CEO in 241
March 2017 [32], and he was CEO of Baxalta prior its acquisition by Shire in June 242
2016 [33]. Also the indirect link Abbott → Advanced Medical Optics → Johnson & 243
Johnson contributes to the Abbott → Johnson & Johnson hidden link. Indeed 244
Advanced Medical Optics, also known as Abbott Medical Optics, has been acquired by 245
Johnson & Johnson in February 2017 [34]. Concerning the rare renal diseases sector the 246
most intense hidden link among diseases belonging to the same category are: Familial 247
hypocalciuric hypercalcemia → Gitelman syndrome as both are hypocalciuric 248
diseases [35], the inversed link Gitelman syndrome → Familial hypocalciuric 249
hypercalcemia, Juvenile nephronophthisis → Bardet–Biedl syndrome as 250
nephronophthisis and Bardet–Biedl syndrome typical cited examples of ciliopathies, 251
Townes–Brocks syndrome → Branchio-oto-renal syndrome as both of these syndrome 252
imply sensorineural hearing loss [36]. Between diseases belonging to different category 253
we observe the notable hidden links: Alport syndrome → Oculocerebrorenal syndrome 254
(the inverted hidden link is also present but less intense) as both are examples of genetic 255
cause of cataract in childhood or early life [37], Denys–Drash syndrome → Perlman 256
syndrome both leading to a high risk of Wilms’ tumor [38, 39]. The most interesting 257
hidden links are those appearing between pharmaceutical companies and rare renal 258
diseases. The most intense one is Alexion → Fabry disease. Indeed Alexion 259
Pharmaceuticals acquired in May 2015 Synageva BioPharma Corp. which is a company 260
dedicated to rare diseases and in particular to Fabry disease [40]. Also with a somewhat 261
less intensity, we observe hidden links from BioMarin and Vertex to Fabry disease. Here 262
indirect pathways through Wikipedia going from Alexion, BioMarin, or Vertex to Fabry 263
diseases are not evident to find as it is the case for hidden links only between 264
pharmaceutical companies or between rare renal diseases. 265
Network structures 266
As the Gpr matrix component of the Nr ×Nr reduced Google matrix GR gives trivial 267
results already known from a direct PageRank analysis of the N ×N global Google 268
matrix, we use the Grr +Gqr matrix component to infer an effective reduced network 269
between possibly the Nr nodes of interest. 270
First we build the reduced network of interactions between the Nr = Nph +Nc 271
nodes of interest constituted by the Nph = 34 pharmaceutical companies and the 272
Nc = 195 countries (see Fig. 6). The reduced network construction rules are described 273
in the caption of Fig. 6. At the first level we take the top 5 companies in PageRank list 274
(Table 1) and trace the links from a company to two countries and two other companies 275
providing these links have the largest column matrix elements in Grr +Gqr. Then the 276
process is repeated to other levels from the newly added companies. The process is 277
stopped when no new companies can be added. We obtain a compact reduced network 278
of 15 pharmaceutical companies over the 34 initially selected, and 12 of these constitute 279
the top 12 of the PageRank list (Table 1). The 3 remaining companies are nevertheless 280
in the top 9 of the largest market capitalization since 2000. 281
From this network, following direct links (black arrows), i.e., hyperlinks from 282
Wikipedia articles, we see, e.g., that for Bayer the closest companies are Sanofi and 283
Roche and the two country friends are Germany, where its main office is located, and 284
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Fig 6. Reduced network of pharmaceutical companies with the addition of their best connected countries.
We consider the first five pharmaceutical companies from the Wikipedia PageRank list (see Tab. 1). Each one of these
companies are represented by purple circles ( ) placed along the main grey circle. From these five most influential
pharmaceutical in Wikipedia, we determine the two best connected companies, i.e., for a pharmaceutical company ph, we
determine the two companies ph1 and ph2 giving the highest (Grr +Gqr)ph1 or 2,ph values. If not already present in the
network, we add these best connected companies along secondary circles centered on the previous companies. Also from the
initial five pharmaceutical companies we determine the two best connected countries, i.e., for a company ph, we determine the
two countries c1 and c2 giving the highest (Grr +Gqr)c1 or 2,ph values. From the newly added pharmaceutical of the first
iteration, we determine the two best connected pharmaceutical companies and the two best connected countries. This
constitutes the second iteration, an so on. At the fourth iteration of this process, no new pharmaceutical companies are
added, and consequently the network construction process stops. The links obtained at the first iteration are represented by
plain line arrows, at the second iteration by dashed line arrows, at the third iteration by dashed-dotted line arrows, and at the
fourth iteration by dotted line arrows. Black color arrows correspond to links existing in the adjacency matrix (direct
hyperlinks in Wikipedia), and red color arrows are purely hidden links absent from the adjacency matrix but present in Gqr
component of the reduced Google matrix GR. The obtained network is drawn with the Cytoscape software [41]. Countries are
marked by their ISO 3166-1 alpha-2 codes.
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Belarus. These two links are direct ones from Bayer page in Wikipedia. Here Belarus is 285
cited as an example of country from the Commonwealth of Independent States (CIS) 286
where over-the-counter drug business was developing; for that purpose Bayer acquired 287
in June 2008 Sagmel, Inc. who was already implanted in CIS [42,43]. For Pfizer the two 288
company friends are GlaxoSmithKline and Johnson & Johnson while two country 289
friends are Italy and Ireland. All these direct links are easily explainable looking 290
through hyperlinks inside Wikipedia articles. Direct links between companies testifies 291
from major transactions between them reported in devoted Wikipedia articles. These 292
direct links gives a compact picture of pharmaceutical companies relationships. The non 293
obvious hidden links (red arrows in Fig. 6) are potentially more interesting. Here, most 294
of the hidden links points to US, highlight the fact that most of the pharmaceutical 295
companies are American. 296
The reduced network of interactions between the Nph = 34 pharmaceutical 297
companies and the Ncr = 37 cancer types is shown in Fig. 7. At each level, it shows two 298
closest company friends and two cancer types. The construction rules are the same as in 299
Fig. 6. The structure of the reduced network between pharmaceutical companies 300
remains the same as in Fig. 6. The reduced network gives the most strong links from a 301
company to the related types of cancer. We observe a clear polarization toward breast 302
cancer, since 10 of the 15 pharmaceutical companies preferentially point to breast 303
cancer, the Wikipedia article of which is the second most influential article among the 304
37 articles devoted to cancer types [20]. The second and third most connected cancer 305
type are leukemia and lung cancer which are preferentially pointed by 4 and 3 306
pharmaceutical companies respectively. Although the (list lung cancer, breast cancer, 307
and leukemia) constitutes the top 3 of the most influential cancer types in 308
Wikipedia [20], we observe the peculiar interest to breast cancer from pharmaceutical 309
companies. Looking with more details, Pfizer and GlaxoSmithKline are mostly linked to 310
breast and leukemia cancers; Bayer to breast and thyroid cancers. Johnson & Johnson 311
has most strong links to leukemia and ovarian cancers. For Novartis the most strong 312
links are to melanoma and breast cancers. Links to cancers for other companies and 313
also well visible in Fig. 7. We argue that our REGOMAX approach allows to determine 314
from Wikipedia the main orientations of pharmaceutical companies in their treatments 315
of cancers. From Fig. 7 we also see that in addition to direct links (black arrows) the 316
indirect links (red arrows) play very important role. 317
The reduced network of pharmaceutical companies and rare renal diseases is shown 318
in Fig. 8. Its construction rules are the same as for Figs. 6 & 7. Again the network 319
structure of the pharmaceutical companies remains the same as in Figs. 6 & 7. Since 15 320
pharmaceutical companies are presents, 30 preferentially connected rare renal diseases 321
could have potentially emerged from this reduced network, but in fact only 10 rare renal 322
diseases are presents. From this network we directly see the main orientations of a 323
company to specific rare renal diseases. We observe a strong polarization toward Fabry 324
disease (Kr = 3 in Table 2) since 12 of the 15 pharmaceutical companies point to Fabry 325
disease. The second and third most connected rare renal diseases are Alport syndrome 326
(Kr = 1 in Table 2) with 5 ingoing links and Kallmann syndrome (Kr = 4 in Table 2) 327
with 3 ingoing links. Looking with more details, Pfizer has the most strong links to 328
Kallmann syndrome and Fabry disease. GlaxoSmithKline is linked to Fabry disease and 329
medullary cystic kidney disease while bayer is oriented to renal agenesis and familial 330
renal amyloidosis disease. For Johnson & Johnson the main orientations are Alport 331
syndrome and Fabry disease. Novartis is mainly linked to renal tubular acidosis and 332
Fabry disease. We observe that none of the articles devoted to the largest market 333
capitalization pharmaceutical companies cite any of the rare renal diseases, thus all the 334
connections from pharmaceutical companies to rare renal diseases are indirect hidden 335
links (red arrows in Fig. 8), confirming indeed the effective status of orphan diseases. 336
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Fig 7. Reduced network of pharmaceutical companies with the addition of their best connected cancers.
The construction algorithm is the same as the one used to generate Fig. 6 excepting that we replace at each iteration the two
best connected countries by the two best connected cancers. Pharmaceutical companies are represented by purple circles ( )
and cancers by green circles ( ).
We also present the friendship network between companies and infectious diseases 337
studied in [19] in SupInfo Fig. S2. 338
Sensitivity of countries to pharmaceutical companies 339
To see the global influence of a specific pharmaceutical company on world countries we 340
use the PageRank sensitivity D described in Section Reduced Google matrix. 341
In Fig. 9 we show the sensitivity of world countries to two companies, Pfizer and 342
Bayer. The two most sensitive countries for Pfizer are Ireland and Italy in correlation 343
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Fig 8. Reduced network of pharmaceutical companies with the addition of their best connected rare renal
diseases. The construction algorithm is the same as the one used to generate Fig. 6 excepting that we replace at each
iteration the two best connected countries by the two best connected rare renal diseases. Pharmaceutical companies are
represented by purple circles ( ) and rare renal diseases by red circles ( ) for congenital abnormalities of the kidney and
urinary tract, blue circles ( ) for glomerular diseases, gold circles ( ) for renal tubular diseases and metabolic diseases, cyan
circles ( ) for nephrolithiasis, and green circles ( ) for ciliopathies.
with the most strong direct links shown in Fig. 6. Italy is present here for historical 344
reasons as calcium citrate used to produce citric acid were supplied to Pfizer by Italy 345
until a shortage caused by World War I which forced Pfizer chemists to develop 346
fermentation technology to obtain citric acid from sugar using a fungus, this technology 347
were then used massively to produce antibiotic penicillin during World War II [45]. In 348
2016, Pfizer tempted to acquire the Allergan, an Irish–tax registered pharmaceutical 349
company, in order to create the world’s largest drugmaker and to relocate its 350
headquarters in Ireland to decrease taxes. The deal was called-off after US Treasury 351
adopted new anti tax inversion rules [46]. The next most Pfizer impacted countries are 352
Canada, Australia, and New Zealand. There is no direct link between Pfizer and these 353
countries. Among the shortest indirect paths we have, e.g., Pfizer → Terre Haute → 354
Canada, Pfizer → Wyeth → Australia, and Pfizer → Helen Clark → Judicial 355
Committee of the Privy Council → New Zealand. Pfizer is present in Canada since 356
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Fig 9. Sensitivity of countries to Pfizer company (top panel) and to Bayer
company (bottom panel). A country c is colored according to its diagonal
PageRank sensitivity D(ph→ c, c), where ph is the pharmaceutical company. Color
categories are obtained using the Jenks natural breaks classification method [44].
fifties, and in 2012 Pfizer’s Canadian division was recognized as one of the 15 best 357
places to work in Canada [47]. In 2009, Pfizer acquired Wyeth which supplied a 358
pneumococcal vaccine approved for young children in Australia [48]. Wikileaks revealed 359
that in 1990 Pfizer was lobbying in the US against New Zealand considering its drug 360
buying rules as restrictive; Helen Clark was at that time New Zealand Health 361
minister [49]. For Bayer the most sensitive countries are Belarus, Ukraine and Germany. 362
Indeed, the article Bayer has direct links to Belarus and Ukraine. There is also direct 363
April 20, 2019 17/26
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/614016doi: bioRxiv preprint first posted online Apr. 29, 2019; 
link to Germany and many indirect links to it since the company is located in Germany. 364
It is possible that Germany is less sensitive compared to Ukraine and Belarus since its 365
PageRank probability is significantly higher. We retrieve here Belarus and Ukraine, 366
members of CIS, as it is explained in Section Network structures. Also India appears as 367
it host a part of Bayer Business Services [50]. 368
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Fig 10. Sensitivity of countries to rare renal diseases; here to Kallmann
syndrome (top panel) and to Bardet–Biedl syndrome (bottom panel). A country c is
colored according to its diagonal PageRank sensitivity D(rd→ c, c), where rd is the
rare renal disease. Color categories are obtained using the Jenks natural breaks
classification method [44].
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Sensitivity of countries to rare renal diseases 369
In Fig. 10 we present the PageRank sensitivity of countries to Kallmann syndrome and 370
Bardet–Biedl syndrome. For Kallmann syndrome the most sensitive countries are 371
Switzerland, Germany and Spain. From Kallmann syndrome many paths converge 372
toward Germany, we have, e.g., the direct link Kallmann syndrome → Germany, and, 373
e.g., the indirect link Kallmann syndrome → Franz Josef Kallmann → Germany. Franz 374
Josef Kallmann who gave the first description of this disease was a German born 375
geneticist. The Wikipedia article devoted to Kallmann syndrome points to Switzerland 376
trough a direct link and an indirect link, Kallmann syndrome → Lausanne University 377
Hospital → Switzerland. The Lausanne University Hospital is cited as one of the main 378
research research facility on this disease [51]. Also the Spanish doctor Aureliano Maestre 379
de San Juan noted the link between anosmia and hypogonadism (Kallmann syndrome 380
→ Aureliano Maestre de San Juan → Spain). Country sensitivity appears due to the 381
combination of direct and indirect links captured by the REGOMAX algorithm. 382
For Bardet–Biedl syndrome the most sensitive countries are Burkina Faso, Norway 383
and Romania. Here there are no direct links to these countries from the article of 384
Bardet–Biedl syndrome [52]. The indirect link to Romania appears since Arthur Biedl 385
was born in today Romania. Indirect paths leading to the other most sensitive countries 386
are difficult to find. 387
We also present the sensitivity of pharmaceutical companies to cancers and rare 388
renal disease respectively in Fig. S3 and Fig. S4 in Section Supplementary Information. 389
Discussion 390
We use the reduced Google matrix (REGOMAX) algorithm for analysis of English 391
Wikipedia network with more than 5 million articles. The analysis is focused on 195 392
world countries, 34 largest biotechnology and pharmaceutical companies, 47 rare renal 393
diseases and 37 types of cancer. The algorithm allows to construct the reduced Google 394
matrix of these entries taking into account the direct and indirect links between them. 395
While the direct links are directly present in the global Wikipedia network the indirect 396
links are obtained with the REGOMAX summing the contributions between entries 397
from all pathways connecting them via the global network. With the reduced Google 398
matrix we determine the interaction networks between companies and world countries, 399
companies and rare renal disease, companies and cancers. From the sensitivity of 400
PageRank probabilities we obtain the influence of specific companies on world countries. 401
This approach also provides the sensitivity of world countries to specific rare renal 402
diseases. We obtain the most influential and communicative pharmaceutical companies 403
showing that the top PageRank positions belong to the companies which are not at all 404
at the top list of market capitalization. We argue that the improvement of Wikipedia 405
articles of specific pharmaceutical companies can increase their world wide visibility 406
without significant additional investments. Our study shows that the knowledge 407
accumulated at Wikipedia can be efficiently analyzed by the REGOMAX algorithm 408
determining the effective interactions between specific Wikipedia articles being of 409
interest for researchers. 410
Acknowledgments 411
This work was supported in part by the Pogramme Investissements d’Avenir 412
ANR-11-IDEX-0002-02, reference ANR-10-LABX-0037-NEXT (project THETRACOM). 413
This work was also supported in part by the Programme Investissements d’Avenir 414
April 20, 2019 19/26
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/614016doi: bioRxiv preprint first posted online Apr. 29, 2019; 
ANR-15-IDEX-0003, ISITE-BFC (project GNETWORKS) and by Bourgogne 415
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Supplementary Information 417
In Fig. S1 we present in local PageRank Kr – CheiRank K
∗
r indexes plane the set of 418
selected Wikipedia articles described in Section Datasets. In Fig. S2 we show the 419
friendship network of interactions between pharmaceutical companies and infections 420
diseases studied in [19]. 421
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Fig S1. Distribution of the May 2017 English Wikipedia articles in the
relative PageRank Kr – CheiRank K
∗
r indexes plane for pharmaceutical
companies and countries (top left panel), and cancer types (top right
panel), and infectious diseases (bottom left panel), and rare renal diseases
(bottom right panel). The Nph = 34 pharmaceutical companies are represented by
purple circles ( ), the Nc = 195 countries by white circles (©), the Ncr = 37 cancer
types by green circles ( ), the Nd = 230 infectious diseases by red circles ( ), and the
Nrd = 47 rare renal diseases by gold circles ( ).
We also show that the REGOMAX analysis allows to determine the inter-sensitivity 422
of pharmaceutical companies to cancers and rare renal diseases. We show the sensitivity 423
of 34 pharmaceutical companies to 37 cancers and 47 rare renal diseases (and vise versa) 424
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Fig S2. Reduced network of pharmaceutical companies with the addition of their best connected infectious
diseases. The construction algorithm is the same as the one used to generate Fig. 6 excepting that we replace at each
iteration the two best connected countries by the two best connected infectious diseases. Pharmaceutical companies are
represented by purple circles ( ) and infectious diseases by red circles ( ) for bacterial type diseases, green circles ( ) for
viral type diseases, gold circles ( ) for parasitic type diseases, and cyan circles ( ) for fungal type diseases. The list of
infectious diseases is available in [19].
in Fig. S3 and Fig. S4 respectively. We note the very strong matrix element in Fig. S4 425
(red square) between Shire and Fabry disease appears due to the drug Replagal which is 426
a treatment for this disease and which is produced by Shire company. 427
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